<DOC>
	<DOCNO>NCT02593188</DOCNO>
	<brief_summary>The purpose propose study acquire additional data ( include assessment anti-rHuPH20 antibody ) long-term safety HYQVIA ass prescribe treatment regimen treatment administration routine clinical practice .</brief_summary>
	<brief_title>Non-Interventional Post-Marketing Safety Study Long-Term Safety HYQVIA ( Global )</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<criteria>1 . Participant require immunoglobulin treatment primary immunodeficiency disease ( PIDD ) 2 . Participant age compatible local package insert requirement 3 . Participant prescribed start treatment HYQVIA ( Immune Globulin ( Human ) 10 % rHuPH20 ) 4 . Participant willing able comply requirement protocol . 5 . Female participant childbearing potential agrees inform investigator becomes pregnant , plan become pregnant course study 1 . Participant know hypersensitivity component medicinal product 2 . Participant participate interventional clinical study involve medicinal product device within 30 day prior enrollment schedule participate interventional clinical study involve medical product device course study 3 . Participant family member employee investigator 4 . Participant plan become pregnant , pregnant breastfeeding time enrollment</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>